Venetoclax treatment combinations show benefit as first-line and follow-up therapy for adults with acute myeloid leukemia (AML), as well as patients who relapse after receiving allogeneic stem cell transplants.
Why This Matters
Failure of conventional induction chemotherapy and posttransplant relapse are key challenges in AML, with limited therapeutic options, particularly for the elderly and patients with comorbidities.
The study was a single-center review of 56 adults (mean age, 66.5 years) who were either treatment naive or had relapsed or recurrent disease. They were treated with venetoclax combined with either hypomethylating agents or low-dose cytarabine in 28-day cycles.
Eighteen patients received first-line therapy, 23 were treated after failure with conventional induction chemotherapy, and 15 were treated after relapse from stem cell transplant. Median follow-up was 4.7 months.
In the first-line setting, median overall survival from the start of venetoclax treatment was 13.3 months, and the overall response rate was 61.1%.
Following transplant relapse, overall survival was 4 months, and overall response rate was 42.8%. Among patients who underwent a subsequent transplant, median overall survival was 11.5 months from the start of venetoclax treatment.
This is a summary of preprint research led by Ulf Schnetzke, MD, Jena University Hospital, Germany, and was provided to you by Medscape. The study has not yet been peer reviewed. The full text is published on Research Square.
M. Alexander Otto is a physician assistant with a master’s degree in medical science. He is an award-winning medical journalist who has worked for several major news outlets before joining Medscape. He is an MIT Knight Science Journalism fellow. Email: [email protected]
Lead Image: Getty Images
Medscape Medical News © 2021
Send news tips to [email protected].
Cite this: Venetoclax Shows Promise as AML Treatment Option – Medscape – Nov 22, 2021.
Content Source: https://www.medscape.com/viewarticle/963415?src=rss